NCT04342663View on ClinicalTrials.gov

A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

August 20, 2020

Study Completion Date

December 12, 2020

Conditions
COVID 19Coronavirus
Interventions
DRUG

Fluvoxamine

Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 300mg per day (3 capsules per day) as tolerated.

DRUG

Placebo

Randomized to either fluvoxamine or placebo for approximately 15 days. Will take up to 3 capsules per day as tolerated.

Trial Locations (2)

62220

BJC, Belleville

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT04342663 - A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection | Biotech Hunter | Biotech Hunter